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an elementary school-located influenza
vaccination program–Results from a
randomized controlled trial
Byung-Kwang Yoo1*, Sharon G. Humiston2, Peter G. Szilagyi3, Stanley J. Schaffer4, Christine Long5
and Maureen Kolasa6Abstract
Background: School-located vaccination against influenza (SLV-I) has the potential to improve current suboptimal
influenza immunization coverage for U.S. school-aged children. However, little is known about SLV-I’s cost-effectiveness.
The objective of this study is to establish the cost-effectiveness of SLV-I based on a two-year community-based
randomized controlled trial (Year 1: 2009–2010 vaccination season, an unusual H1N1 pandemic influenza season,
and Year 2: 2010–2011, a more typical influenza season).
Methods: We performed a cost-effectiveness analysis on a two-year randomized controlled trial of a Western
New York SLV-I program. SLV-I clinics were offered in 21 intervention elementary schools (Year 1 n = 9,027; Year 2
n = 9,145 children) with standard-of-care (no SLV-I) in control schools (Year 1 n = 4,534 (10 schools); Year 2 n = 4,796
children (11 schools)). We estimated the cost-per-vaccinated child, by dividing the incremental cost of the intervention
by the incremental effectiveness (i.e., the number of additionally vaccinated students in intervention schools compared
to control schools).
Results: In Years 1 and 2, respectively, the effectiveness measure (proportion of children vaccinated) was 11.2 and 12.0
percentage points higher in intervention (40.7 % and 40.4 %) than control schools. In year 2, the cost-per-vaccinated
child excluding vaccine purchase ($59.88 in 2010 US $) consisted of three component costs: (A) the school costs ($8.25);
(B) the project coordination costs ($32.33); and (C) the vendor costs excluding vaccine purchase ($16.68), summed
through Monte Carlo simulation. Compared to Year 1, the two component costs (A) and (C) decreased, while the
component cost (B) increased in Year 2. The cost-per-vaccinated child, excluding vaccine purchase, was $59.73 (Year 1)
and $59.88 (Year 2, statistically indistinguishable from Year 1), higher than the published cost of providing influenza
vaccination in medical practices ($39.54). However, taking indirect costs (e.g., averted parental costs to visit medical
practices) into account, vaccination was less costly in SLV-I ($23.96 in Year 1, $24.07 in Year 2) than in medical practices.
Conclusions: Our two-year trial’s findings reinforced the evidence to support SLV-I as a potentially favorable system to
increase childhood influenza vaccination rates in a cost-efficient way. Increased efficiencies in SLV-I are needed for a
sustainable and scalable SLV-I program.
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Seasonal influenza poses a substantial disease burden on
children [1, 2]. In 2008, the United States Advisory Com-
mittee on Immunization Practices (ACIP), the American
Academy of Pediatrics (AAP) and the American Academy
of Family Physicians (AAFP) recommended universal an-
nual seasonal influenza vaccination for all children aged
6 months to 18 years [3]. This recommendation was de-
signed to protect children because influenza is a common
cause of pediatric outpatient visits [4–6], hospitalizations
[7–14] and deaths [15, 16]. Further, by reducing spread of
disease, influenza vaccination for children can also reduce
influenza-related morbidity and mortality among adults
[17–19] as well as school absenteeism among children
and teachers [20].
Despite these recommendations, vaccination coverage
among school-aged children remains far below the most
recent version of the Healthy People 2020 goal of 70 %
coverage for all children [21, 22]. For the 2012–13 influ-
enza season, only 58.6 % of 5–12 year olds and 42.5 % of
13–17 year olds received influenza vaccination [22]. Vac-
cinating all children within their primary care practices
is a major challenge.
To attempt to increase vaccination coverage among
school-aged children, some communities have imple-
mented school-located vaccination against influenza
(SLV-I) [23–25]. Cawley and associates conducted a
systematic literature review and concluded that SLV-I
is a promising option to achieve the expanded ACIP influ-
enza vaccination recommendation [26]. They highlighted
the need for well-controlled trials to establish the cost-
effectiveness of specific influenza vaccination strategies.
Some experts believe that “the greatest need for future U.S.
[SLV-I] program implementation is the development of a
financially sustainable model that can be replicated annu-
ally on a national scale” [23].
We conducted a community-based randomized con-
trolled trial (RCT) of SLV-I among elementary school chil-
dren in Monroe County, New York, during the fall seasons
of 2009 and 2010 to examine the effectiveness (i.e., im-
provement in influenza vaccination rates), cost, and cost-
effectiveness of SLV-I. The demonstration project’s design
and effectiveness for Years 1 and 2 have been reported
[27]. In addition, we have reported the project’s cost-
effectiveness for Year 1 [28], which was the 2009 H1N1
pandemic year, and therefore unusual [27–29]. Analyzing
the project’s Year 2 cost-effectiveness, a more typical influ-
enza season than Year 1, could yield unique contributions
to the literature. Specifically, the SLV-I program’s Year 2
might have been more efficient than Year 1 because of in-
creased staff efficiency or program improvements (e.g., due
to low utilization of a second clinic at each school in Year
1, only one clinic per school was offered in Year 2). Con-
versely, Year 2 might have been less efficient than Year 1because of the parent demand in Year 1 being increased
partly by the H1N1 influenza pandemic.
This paper reports on the Year 2 cost and cost-
effectiveness of this SLV-I model, and compares these
with corresponding values for Year 1. Our hypotheses
were that the average cost-per-vaccinated child in SLV-I
during Year 2 would be (1) lower than that observed in
Year 1 and (2) comparable or lower than that observed in
medical practices [30], when accounting for the costs to
deliver vaccines and parents’ costs to visit medical prac-
tices for their child’s influenza vaccination. Our supple-
mental hypothesis was that in a Year 2 cost-effectiveness
analysis, SLV-I could be cost-saving for society compared
to “no vaccination.”Methods
The methods for data collection and analysis in Year 2
followed those in Year 1 [27, 28]. The study designs of
Years 1 and 2 of this study were the same, with
randomization of elementary schools into 21 interven-
tion (SLV-I) schools (9027 students in Year 1; 9145
students in Year 2) and control schools (10 schools,
4534 students in Year 1; 11 schools, 4796 students in
Year 2) (Table 1). Randomization assignments from
Year 1 generally remained constant in Year 2 [27].
Based on the New York State Immunization Informa-
tion System data, influenza vaccine coverage in 2008
(prior to Year 1) was similar for students in SLV-I and
control schools (P > 0.2) [27]. The number of vaccin-
ation clinics at each school (two-per-school in Year 1;
one-per-school in Year 2) differed by year. To make a
fair comparison between the costs of the program in
Years 1 and 2, we did not include vaccinations deliv-
ered at the second in-school clinic in Year 1. Our cost
effectiveness analysis models derived all of the effect-
iveness parameters and most of the cost parameters
from our community-based RCT (the Trial Registration
Number for the RCT is ClinicalTrials.govNCT01224301).
The Research Subjects Review Boards of the University of
Rochester and the Monroe County Department of Public
Health approved this study, including the informed con-
sent procedure, in 2009.)
SLV-I clinics were held between 11/03/09 and 11/20/
09 in Year 1 and between 11/2/2010 and 11/18/2010 in
Year 2. A vaccination vendor administered either live
attenuated (LAIV) or inactivated (TIV) seasonal influ-
enza vaccines. Influenza vaccinations administered in
the SLV-I clinics were recorded in the mass vaccina-
tor’s database and analyzed in this study. Influenza
vaccination rates outside the SLV-I clinics for both
intervention and control schools were assessed by re-
view of New York State Immunization Information
System (NYIIS).
Table 1 Vaccination rates in school-located seasonal influenza vaccination (SLV-I) schools and control schools during Year 1 (2009–2010 season) and Year 2 (2010–2011 season)
Year 1 (2009–2010)a Year 2 (2010–2011)
SLV-I schools Control schools Difference between SLV-I
and Controlb
SLV-I schools Control schools Difference between SLV-I
and Controlb
Students % Total Students Students % Total Students Students % Total Students Students % Total Students
TOTAL STUDENTS 9,027 100 % 4,534 100 % 0 % 9,145 100 % 4,796 100 % 0 %
Not vaccinated 5,356 59.3 % 3,195 70.5 % −11.2 % 6,486 59.6 % 3,432 71.6 % −12.0 %
Total vaccinated 3,671 40.7 %* 1,339 29.5 %* 11.2 %d*** 3,698 40.4 %** 1,364 28.4 %** 12.0 %d***
Vaccinated elsewherec 2,474 27.4 % 1,339 29.5 % −2.1 % 2,659 29.1 % 1,364 28.4 % 0.6 %
Vaccinated at SLV-I 1,197 13.3 %c n/a n/a 13.3 % 1,039 11.4 % n/a n/a 11.4 %
n/a: not applicable
a: Only first clinics at each SLV-I school (excluding the vaccinated children at the second vaccination clinics (2.0 % among all students in Year 1))
b: The differences in the proportion between the column of “SLV-I schools (% Total Students)” and “Control schools (% Total Students)”
c: Identified as receiving at least the 1st dose outside the SLV-I schools in the New York State Immunization Information System (NYSIIS)
d: Primary effectiveness measure included in our cost-effectiveness analysis model
*: 40.7 % was significantly greater than 29.5 % (p-value < 0.0001) in Year 1
**: 40.4 % was significantly greater than 28.4 % (p-value < 0.0001) in Year 2
***: Primary effectiveness: 11.2 % in Year 1 was marginally smaller than 12.0 % in Year 2 (p-value = 0.092)
Yoo
et
al.BM
C
H
ealth
Services
Research
 (2015) 15:511 
Page
3
of
12
Yoo et al. BMC Health Services Research  (2015) 15:511 Page 4 of 12Cost-effectiveness analysis (CEA)
We estimated the incremental cost-effectiveness ratio
(ICER) by dividing the incremental cost (i.e., the differ-
ence in cost of vaccination in intervention schools minus
the cost of vaccination in control schools (i.e., a refer-
ence group)) by the incremental effectiveness (i.e., the
number of additionally vaccinated students in interven-
tion schools compared to control schools). Both effect-
iveness and cost measures are defined below.
Effectiveness measure
We defined effectiveness as the difference between the
proportion of students who received ≥1 seasonal influenza
vaccine anywhere (either at school or elsewhere) among
students enrolled in intervention vs. control schools. This
broad effectiveness measure was used because the inter-
vention’s communication activities could have motivated
parents to have their children vaccinated at either a med-
ical practice or their schools.
Cost measures
We calculated all costs in 2010 US $, adjusting with the
consumer price index (CPI) when needed [31]. We esti-
mated three “program costs” incurred by this study: (A)
school costs, (B) project coordination costs, and (C) vendor
costs, as well as two indirect costs averted by having the
SLV-I program: (D) averted parents’ costs (i.e., costs to visit
medical practices for a child’s influenza vaccination) and
(E) costs averted by disease prevention (i.e., both reduced
influenza-related medical costs among all household mem-
bers and reduced loss of parental productivity related to
caring for a sick child). “Net Cost” was defined as “Program
costs” (A + B +C) less averted parent costs (D). “Societal
Cost” was defined as “Program costs” (A + B +C) less costs
averted by influenza prevention (E).
Program cost components
Component A (school cost) included non-labor material
cost (e.g., supplies and expenses associated with distribut-
ing information to parents) and labor costs. We calculated
labor cost by multiplying the self-reported school staff
hours by the national mean wage of a relevant job cat-
egory as of May 2010 [32]. Component B (project coord-
ination cost) included the cost incurred by coordinating
activities, but excluded research and evaluation costs.
Component C (vendor costs) comprised the vendor’s
labor (C1) and material costs, including broad items such
as vaccine purchase, the refrigerator for vaccines and sup-
plies. The vendor’s vaccine purchase costs were modeled
in two ways. Our primary analysis, from the societal per-
spective, assigned a vaccine purchase cost (C2) of $12.06/
dose for Year 2, which is the weighted average prices of
federal Vaccine-For-Children (VFC) doses ($10.94 per
dose; 52 % of all doses) and non-VFC doses ($13.26; 48 %)as of May 2010, listed on the CDC website [33]. These
prices assumed that 80 % and 20 % of doses administered
in this demonstration project were TIV and LAIV, respect-
ively, in each year, as was observed in this trial’s Year 1.
[28] Our supplemental analysis, assuming that VFC doses
were free, was performed from the alternative perspective
of school districts, health departments, and insurers (we
included administration costs for private and VFC vac-
cine). In accordance with the Year 1 trail’s observation, the
Year 2 analysis assumed that 52 % of students were VFC-
eligible and, therefore, there was no charge to the vendor
or families for their vaccine. Consequently, the cost item
(C3) is the weighted average of VFC-dose ($0 per dose;
52 % of all doses) and non-VFC dose ($13.26; 48 %). How-
ever, it should be noted that these vaccine doses were not
“free” from a societal perspective. Similarly, the vaccine
prices for Year 1 were cited from the CDC website as of
May 2009 [34].Components D and E
The Components D and E estimated the averted cost for a
household with a child protected by influenza vaccine,
compared to a household with an unvaccinated child.
These cost estimates were assumed to be constant across
two years when expressed in 2010 US $.
Averted parent costs (D) were derived previously [28]
and included the cost of parents’ time [35–37] (two hours
at the national median hourly wage of $21.25) and trans-
portation ($6.42) [38]. Because some children would have
had a medical visit to their primary care practice for rea-
sons other than influenza vaccination during the influenza
vaccination season, we took this into account. The sum of
these averted costs ($21.25*2 h + $6.42 = $48.92) was dis-
counted by 27.1 % (to $35.66) because the Medical Ex-
penditure Panel Survey (MEPS) [39] showed that 27.1 %
of children aged 7 to 12 years had ≥1 primary care visit
between October and January (corresponding to typical
influenza vaccination season). Also, these costs (D) do not
include any medical expenditure, either paid by parents or
incurred at medical practices.
The costs averted by disease prevention (component E)
were derived from the literature. Based on findings from a
large controlled clinical SLV-I trial, Schmier et al. estimated
the averted medical expenditure as $121.46 and the averted
productivity loss as $88.99 (both adjusted to 2010 dollars)
per household, comparing the average costs per household
between intervention and control schools during an influ-
enza season [40]. The former averted medical expenditure
represents the difference in direct influenza disease costs
between intervention and control schools, including the
costs for outpatient, emergency department, hospitalization,
prescribed medication and over-the-counter medication
[40]. The latter averted productivity loss accounted for the
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take care of his/her influenza-infected child [40].
In the Schmier study [40], the average costs averted
by disease prevention (component E) were $210.45
(=$121.46 + $88.99) per household comparing the inter-
vention households (with a 47 % child vaccination rate)
and the control households (with a 2 % child vaccination
rate). On the other hand, because our study’s Component
E represents the per-household averted cost comparing
between households with a 100 % child vaccination rate
and those with a 0 % child vaccination rate, the compo-
nent E is expected to be at least $210.45. However, since
the composition and household size were not assessed in
our study unlike the Schmier study (i.e., 2.59 children and
2.0 adults per household), we made a conservative esti-
mate for the component E as $210.45.
Managing uncertainty
To address the uncertainty of the cost parameters in our
model, we conducted a Monte Carlo simulation in sum-
ming the component costs, (A), (B) and (C1), to estimate
subtotal costs and total costs. We defined a triangular dis-
tribution with modal, minimum and maximum values for
each component cost. The modal value was assumed to be
equal to the overall mean cost of all SLV-I schools. The
minimum and the maximum values, for the components
(A) and (C1), were determined among the eleven data
points from the individual SLV-I schools, according to our
Year 1 analysis, since school-related costs appeared to vary
widely by school [28]. Regarding the component B (project
coordination cost), we used 4 data points derived from 4
groups of schools based on the geographic area (urban/
rural) and the intensity of an intervention outreach activity
(high/low). The mean and the 95 % confidence interval
(CI) of the simulation results with 10,000 iterations were
reported, where 95 % CI was assumed to be equal to the
range of the 2.5th and 97.5th quantiles of the iterations.
Comparison with practice-located vaccination
We determined that SLV-I would be less costly than
practice-located vaccination if the estimated cost-per-
vaccinated child for SLV-I were below the median/mean
($22.17/$39.54 in 2010 US $) cost-per-vaccinated child for
practice-located influenza vaccination as reported in our
past study [28, 30]. For this comparison, we excluded the
vaccine purchase cost from both SLV-I costs and medical
practices’ costs [28, 30]. Finally, we subtracted the averted
parent’s costs (Component D = $35.66) from the program
costs of the SLV-I program.
Results
Effectiveness measures
The overall influenza vaccination rates (including vaccina-
tions received in schools and at provider’s offices) in Years1 and 2 were 40.7 % and 40.4 %, respectively, among
children attending SLV-I schools compared to 29.5 % and
28.4 %, respectively, among those attending control
schools (Table 1). Thus, the net effects of SLV-I was an
11.2 percentage point higher vaccination rates in Year 1
and a 12.0 percentage point higher vaccination rate in
Year 2, suggesting a substantial impact of SLV-I in both
the H1N1 Year 1 and the more typical seasonal influenza
season in Year 2. These overall influenza vaccination rates
of the SLV-I schools were slightly lower than among those
aged 5–12 years enrolled in two nationally representative
studies (i.e., National Health Interview Survey (NHIS) and
National Immunization Survey (NIS)), e.g., 41.3 %-42.2 %
during Year 1 and 45.9 %-54.7 % during Year 2 [41].
Cost measures
The number of students vaccinated in SLV-I schools
(Table 1) was used as the denominator for the cost meas-
ure estimation and cost effectiveness analysis. The project
coordination cost (B) per vaccinated-child was higher in
Year 2 than Year 1, ($32.33 vs. $25.35), more than offset-
ting increased efficiencies in other costs (Table 2). In con-
trast, school costs (A) per vaccinated-child were lower in
Year 2 than Year 1, ($8.25 vs. $9.92) as were the vendor
costs (C) per vaccinated-child ($28.74 vs. $33.99). Since
the vaccine purchase costs (C2) could vary substantially
depending on the proportion of vaccine-for-children
(VFC) eligible children, we made separate costs estimates:
(i) including the vaccine administration cost only (C1) and
(ii) additionally including the vaccine purchase cost (C2).
Cost effectiveness analysis (CEA)
Comparison between years 1 and 2
The Subtotal and Total costs in Table 2 present the CEA
results, i.e., ICER estimates based on the Monte Carlo
simulation, that enable us to compare the overall SLV-I
program performance between Years 1 and 2. Our re-
sults showed that the ICER estimates for all types of
Subtotal and Total costs were not significantly different
between Years 1 and 2. Thus, our first hypothesis – that
the average cost per vaccinated child in SLV-I schools
would be lower during Year 2 than Year 1–was not sup-
ported. Note that despite differences in point (mean) es-
timates, there was marked overlap in the 95 % CIs
between Years 1 and 2.1
Comparison with practice-located vaccination
When we consider only program costs, we find that SLV-I
costs were higher than costs observed in medical practices.
Specifically, based on the Subtotal Program Cost 2 (based
only on Components A + B +C1), the mean ICER estimates
were $59.73 in Year 1 and $59.88 in Year 2. These mean
estimates and the lower bounds of 95 % CI $48.26 in Year
1 and $47.69 in Year 2) were all higher than previously
Table 2 Cost-effectiveness analysis of school-located seasonal influenza vaccination (SLV-I) during the 2009–2010 season (Year 1)a and the 2010–2011 season (Year 2) (all 2010 US $)b;
Unit is incremental cost-effectiveness ratio (ICER)c [$-per-incremental-student-vaccinated in the school-located seasonal influenza vaccination (SLV-I), compared to control schools]
Year 1a Year 2
COMPONENT COSTSd
(A) School coste $9.92 $8.25
($6.41, $14.75)k ($5.33, $12.26)k
(B) Project coordination costf $25.35 $32.33
($16.37, $37.65)k ($20.87, $48.02)k
(C) Vendor cost from the societal perspective (=C1+ C2) $33.99 $28.74
($26.23, $44.76)k ($22.83, $36.84)k
(C1) Vaccine administration
g $21.91 $16.68
($14.15, $32.68)k ($10.77, $24.78)k
(C2) vaccine purchase from the societal perspective
(VFC dose = $10.76 (Year 1) $10.94 (Year 2)h
$12.08 $12.06
(C3) Vaccine purchase from the alternative perspective
of school districts, health departments, and insurers (VFC dose = $0)h
$6.48 $6.37
(D) Averted parents’ costs (i.e., to visit medical practices for
a child’s influenza vaccination)i
$35.66 $35.66
SUBTOTAL COSTSj
Subtotal Net Cost 1: (A + B)-(D) $1.15m $6.64m
(−$7.46, $10.31)l (−$3.93, $17.93)
Subtotal Program Cost 2: (A + B + C1) $59.73 $59.88
($48.26, $71.73)l ($47.69, $72.74)l
Subtotal Program Cost 3: (A + B + C1 + C3) $66.19 $66.06
($54.94, $78.13)l ($53.94, $78.69)l
TOTAL COSTSh
Total Program Cost 1 from the societal perspective: (A + B + C) $71.78 $71.74
($60.32, $83.77)l ($59.75, $84.47)l
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Table 2 Cost-effectiveness analysis of school-located seasonal influenza vaccination (SLV-I) during the 2009–2010 season (Year 1)a and the 2010–2011 season (Year 2) (all 2010 US $)b;
Unit is incremental cost-effectiveness ratio (ICER)c [$-per-incremental-student-vaccinated in the school-located seasonal influenza vaccination (SLV-I), compared to control schools]
(Continued)
Total Net Cost 2 to compare with influenza vaccination in private
pediatric practices: (A + B + C1)-(D)
$23.96n $24.07n
($12.79, $35.99)l ($12.08, $37.00)l
Total Net Cost 3 from the societal perspective accounting for averted
parents’ costs: (A + B + C)-(D)
$36.16 $36.01
($24.82, $48.13)l ($23.93, $48.76)l
a: Only first clinics at each SLV-I school (not including the vaccinated children at the second vaccination clinics (2.0 % among all students) in Year 1)
b: All cost estimates were adjusted to 2010 U.S. dollar values with the consumer price index when needed [31]
c: Incremental cost-effectiveness ratio (ICER) was estimated by dividing the incremental cost (i.e., the difference in cost of vaccination in intervention schools minus the cost of vaccination in control schools (i.e., a
reference group)) by the incremental effectiveness (i.e., the number of additionally vaccinated students in intervention schools compared to control schools). In control schools, some students were vaccinated outside
schools (e.g., medical practices), as summarized in Table 1
d: The values within the parentheses in the rows for COMPONENT COSTS indicate the triangular distributions defined by the modal value, (minimum value and maximum value). The modal value was assumed to be
equal to the overall mean of the SLV-I schools. The minimum and the maximum values were determined among the eleven mean cost estimates from eleven SLV-I schools, following our Year 1 analysis [28]
e: Composed of material cost and labor cost. Material cost includes information distribution (to parents) costs such as paper, mailing, and phone. Labor cost was calculated through “the time spent for the project by
school staffs” multiplied by “category-specific hourly wage (national average)” as of May 2009 [58] and May 2010 [32] for Year 1 and Year 2, respectively
f: Time cost for collection of consent forms, and meeting with school staffs, and vendors. Evaluation research cost was excluded
g: Composed of the vendor’s labor and material costs, including broad items such as the refrigerator for vaccines and supplies
h: 52 % of the administered doses that were provided by Vaccine-for-children (VFC) for free. From a societal perspective, we assigned $10.76 (Year 1) and $10.94 (Year 2) per dose as the vaccine purchase cost, which
is the weighted average prices of TIV (80 % of doses administered in this demonstration) and LAIV (20 %) listed in the CDC website as of May 2009 [34] and May 2010 [33] for Year 1 and Year 2, respectively
i: This (D) averted parents’ costs indicate the costs to visit medical practices for a child’s influenza vaccination, consisting of parents’ time cost [35–37] and transportation cost [38]. These costs do not include any
medical expenditure, either paid by parent or incurred at medical practices
j: The values within the parentheses in the rows for subtotal costs and total costs indicate the mean and 95 % confidence interval of Monte Carlo Simulation results (10,000 iterations) using the distributions defined in
the rows for component costs. The 95 % confidence interval was assumed to be equal to the range of the 2.5th and 97.5th quantiles of the iterations
k: The minimum and the maximum values, for the components (A) and (C1), were determined among the eleven data points from the individual SLV-I schools. Regarding the component (B), we used 4 data points
derived from 4 groups of schools based on the geographic area (urban/rural) and the intensity of an intervention outreach activity (high/low)
l: 95 % confidence interval values (under a Monte Carlo Simulation) are in parentheses
m: Below the lower limit of the cost range ($11.59, $17.38) [per child vaccinated] in the reminder program (using letters and/or automated telephone message) estimated by Lieu et al. [59]
n: Falls between the 25th percentile ($13.88) and the median/mean ($22.17/$39.54) cost [per dose] for providing influenza vaccination in private pediatric practices estimated by Yoo et al. [28, 30]
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mean = $22.17/$39.54) [28, 30].
When also considering indirect averted parent costs (D)
(Total Net Cost 2: Components A + B + C1–D), the mean
ICER estimates would decline to $23.96 in Year 1 and
$24.07 in Year 2. These mean ICER estimates in both
years fall between the 25th percentile ($13.88) and the
mean ($39.54) cost for providing influenza vaccination in
medical practices [28, 30], supporting our second hypoth-
esis that SLV-I costs would be comparable or lower than
practice-based influenza vaccination costs when including
indirect averted parent costs (Component D).
When including indirect costs averted by disease pre-
vention (E), the mean ICER estimate for Year 2 became
negative ((A + B + C)–E = $71.74 - $210.45 = −$-138.71)
(results not shown in Table 2). Negative ICER values in-
dicate that SLV-I is cost saving compared to “no vaccin-
ation” from a broader societal perspective.
Finally, we performed two sets of break-even analyses
for CEA in Year 2 only: (1) Based on the Total Net Cost
3 [(program costs − parent costs) = (A + B + C −D)], we
estimated the threshold level of in-school vaccination
necessary for SLV-I to be cost-saving to society, even if
averted costs due to medical expenditures and lost prod-
uctivity were not included. This would be achieved if the
in-school net vaccination rate were to increase from the
actual level (11.4 % in Year 2) to at least 24.0 %, assum-
ing no change in vaccination rates ‘elsewhere.’ (2) Based
on the Subtotal Program Cost 2 (A + B + C1), we estimated
the level of in-school vaccination necessary for mean cost
in SLV programs and medical practices to be equivalent,
even if averted parents’ costs to visit a medical practice
(D) were not included. This would be achieved if the in-
school vaccination rate were at least 17.6 %, assuming no
change in vaccination rates ‘elsewhere.’Discussion
We had hypothesized that the SLV-I program would
become more efficient in Year 2 of implementation, but
found that the costs and cost-effectiveness of SLV-I
were comparable in Year 2, a routine seasonal influenza
vaccination year, compared to Year 1, the year of pan-
demic H1N1. Project coordination costs (Component
B) were higher in Year 2 than 1, more than offsetting
improved efficiencies in other costs. A detailed com-
parison between the two years offers useful policy im-
plications for SLV-I and can help set future goals to
improve the overall cost-effectiveness of SLV-I during a
more typical season. Additionally, analyses of both
Years 1 and 2 showed that SLV-I could be cost-saving
to society, compared to “no vaccination,” if savings
from the increase in disease prevention under the SLV
program (Component E) were included.Comparison with vaccination in medical practices
When considering program costs alone, the cost to vac-
cinate a child in SLV-I was higher than the previously
calculated cost to vaccinate a child in primary care prac-
tices in the same community. When considering pro-
gram plus averted parent costs for transportation and
time lost from work (i.e., cost component (D)), the cost
to vaccinate a child in SLV-I was comparable or lower
than that in primary care practices. Communities inter-
ested in implementing SLV-I will naturally focus on the
difference between program costs and revenues received
from SLV-I in determining feasibility and sustainability
of SLV-I.
Comparison between year 1 and year 2
Project coordination costs (Component B): The major rea-
son why the SLV-I project was not more cost-effective in
Year 2 than Year 1 was that the project coordination costs
(Component B) increased during Year 2, more than offset-
ting decreases in school and vendor costs (Components A
and C). In Year 2 pre-season, an additional four weeks
was available for planning leading to more time being de-
voted to the process. Variation in responsibility for some
tasks in Years 1 and 2 among school staff and project ad-
ministrative staff may have led to changes in Components
A and B across years. Because of this, we also compared
the sum of Components of A and B – $35.27 (Year 1) was
still lower than $40.58 (Year 2). Given the realities of busy
school personnel and the reduction in school nurses
nationwide, we believe that for SLV-I to be sustainable,
work by school staff would need to be minimized, with
the possible exception of a special pandemic season. Thus,
it is possible that the costs noted in Year 2 may represent
a more generalizable estimate. Regardless of the reasons
for the high costs, it is clear that for SLIV to be sustainable
and scalable, fieldwork costs outside of the school-based
costs would need to be lower than we experienced. Fur-
ther studies are needed to assess the degree to which field-
work costs can be reduced, e.g., costs to coordinate five
school-districts in our trial which imposed much higher
burdens compared a single school-district trial [42].
Comparison of year 2 trial with other studies
Our Year 2 intervention had a moderate impact on in-
fluenza vaccination uptake with an improvement of 12
percentage points (pp). This impact was higher than
that found in other trials, such as those using text mes-
sage reminders (3.7 pp) [43], mail reminders (6.5 pp)
[44], and provider prompts (4.0 pp but statistically in-
significant) [45].
The overall vaccination coverage rates found in our
trial was in the range of rates noted in other studies. For
example, SLV-I trials at the state level in Hawaii and the
three-county level in Minnesota resulted in very high
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ively; however these were not clinical trials, no control
schools existed, and the papers did not report what per-
cent of vaccinations were delivered in school versus in
physician offices. In an SLV-I trial at nineteen elemen-
tary schools in California, coverage varied by school,
with 26.9 %-46.6 % of children in each school receiving
at least one dose of influenza vaccine with a large impact
due to SLV-I; however in this setting control schools had
virtually zero vaccination rates [47].
Unlike other SLV-I trials, our SLV-I trial billed insurers
(or parents if insurance coverage was unknown) for vac-
cines and vaccine administration. We contracted with a
for-profit vendor that delivered the in-school vaccinations,
which were purchased through routine channels or ob-
tained through VFC program. Consequently, the cost esti-
mates from our study are greater than those in other SLV-I
trials that did not include vaccine cost and\or the cost to
bill insurance or Medicaid for vaccines or vaccine adminis-
tration. The cost estimates in other studies in this section
were all adjusted to 2010 US $ with medical care CPI [31].
For instance, our estimate of $59.88 per vaccinated-child
was much lower than that by Kansagra et al. ($80.92) [48],
but considerably higher than that by Schmier and col-
leagues ($6.98) [40], Hull and associates ($10.11) [46],
Effler et al. ($15.66) [25], and Kemp and colleagues
($24.69) [49]. Among these five studies, only Kansagra
et al. and Effler et al. reported the detailed cost items
within the administration cost. Concerning the labor
cost estimates, our estimate ($39.13 per vaccinated-child)
was slightly larger than $33.17 estimated by Kansagra et al.
[48], and much larger than $12.19 estimated by Effler et al.
[25]. The latter lower estimate may have been partly due to
economies of size of their large state-wide program, vaccin-
ating 63,153 children after targeting all children aged
5–13 in Hawaii [25]. Additionally, the studies by
Effler et al. [25] or Hull et al. [46] did not seek third
party reimbursement, which was included as part of the
vendor’s administrative cost (for the billing process) in our
study. Parents were not billed for any fees in the study by
Kemp et al. [49], although our cost estimates includes the
vendor’s billing process costs for parents.
Extensive project staff time was needed to manage
parents’ consent forms–all done on paper – which in-
cluded details of about patient insurance. More efficient
consent systems could reduce future SLV-I program
costs [50, 51].
Material costs incurred by schools and the project coor-
dinators were $4.69 per vaccinated-child, which was simi-
lar to $5.72 (adjusted to 2010 US $ with medical care CPI)
reported by Effler et al. [25]. However, our estimate of the
vendor’s material cost, $13.43 per vaccinated-child, was
much higher than that of $1.64 by Effler et al. [25]. This
difference can be partly explained by our study’s broadercost definition including items such as the refrigerator for
vaccines and non-medical supplies.
Other studies also have concluded that SLV-I may be cost
saving to society, when considering broader indirect costs
[40, 52]. Using secondary datasets only, White and associ-
ates estimated that group-based influenza vaccination was
cost-saving, i.e., saving $6.40 and $55.82 per vaccination, as
compared to individual vaccination at a medical practice
and no-vaccination, respectively [52]. Schmier et al. ana-
lyzed their primary data to conclude that SLV-I is cost-
saving to society, saving $170.31 on average among all
households in intervention schools [40].
In summary, our study, based upon a real-world dem-
onstration and including billing of third party payers,
had higher program costs than most prior SLV-I studies,
resulting in lower cost-effectiveness. Our findings re-
garding indirect parent or societal costs were in line with
those of other studies.
Potential limitations
There was uncertainty in cost estimates in Year 1 that
may affect the comparison with Year 2. As discussed in
the paper describing Year 1 [28], it is difficult to accurately
allocate the fixed costs between first clinics and second
clinics during Year 1 due to the limited available data.
Another limitation is the potentially limited generalizability
of our estimates, which may have been affected by multiple
factors. The effectiveness of SLV-I is sensitive to the propor-
tion of local children vaccinated by medical practices prior
to the school vaccine clinics. For instance, in an area where
medical practices vaccinate a high proportion of children, a
SLV-I program may have a smaller impact on vaccination
coverage. Hence, our SLV-I effectiveness estimates are likely
to be most applicable to other areas where the vaccination
rates achieved by medical practices are similar to those in
our study site, i.e., less than one-third of children were
vaccinated pre-intervention. Second, since influenza
vaccination rates may be influenced by a host of seasonal
influenza factors (e.g., disease severity [53], vaccine avail-
ability [54], media coverage [55]) SLV-I vaccination cover-
age in school and, consequently, effectiveness estimates
could differ from year to year.
Different methods were used to ascertain the vaccinated
status between intervention schools (based on the vendor’s
records and New York State Immunization Information
System (NYSIIS)) and control schools (NYSIIS records
only). This difference could affect the effectiveness measure
within a year, but would not affect the comparison between
Years 1 and 2.
Finally, we derived indirect costs from the literature, not
from our trial. Since we utilized a national-level median
hourly wage among working adults for estimating the in-
direct cost component D, averted parents’ costs, these esti-
mates are expected to be reasonably generalizable. Since
Yoo et al. BMC Health Services Research  (2015) 15:511 Page 10 of 12the magnitude of the other indirect component (E, costs
saving from disease prevention) might be sensitive to the
estimation methods and the seasons analyzed, component
E-related results were not presented in Tables. Our ana-
lysis excluded some relevant, but unmeasured, indirect
costs such as costs due to disruptions of the school day by
SLV-I, and cost savings from decreased absenteeism.
Policy implications
Our findings from a real-world demonstration project indi-
cated that while SLV-I is effective in improving influenza
vaccination rates in school-aged children, project coordin-
ation costs (Component B) remained high during a second
project year. High project coordination costs (Component
B), driven by a substantial amount of effort needed to ob-
tain informed consent and to manage implementation of
the project, more than offset lower school and vendor costs
(Components A and C). Project coordination costs (Com-
ponent B) would need to be reduced through strategies
such as an efficient parent consent and communication
system. Overall, the per-vaccinated child cost estimates of
our SLV-I were higher than those in medical practices and
also higher than typical reimbursement rates. While our
current cost estimates favor SLV-I over medical practices
when we account for averted parental costs to visit medical
practices (Component D), such cost-savings to parents
may not be considered by health systems responsible for
SLV-I. Thus, while costs are not the only consideration in
setting up and sustaining SLV-I [56, 57], the program costs
for SLV-I should be lower than practice-located costs, or at
least lower than or equal to reimbursement rates for SLV-I
to be sustained.
Finally, achieving higher in-school vaccination cover-
age would improve cost-effectiveness. For example, in
this study a net vaccination rate of 17.6 % (rather than
11.4 % found in Year 2) would lead to SLV-I cost esti-
mates being lower than those in medical practices.
Conclusions
Our two-year trial’s findings reinforced the evidence to
support SLV-I as a potentially favorable system to in-
crease childhood influenza vaccination rates in a cost-
efficient way, but increased efficiencies in SLV-I are
needed for a sustainable and scalable SLV-I program.
Endnotes
1For instance, using our primary effectiveness measure
(i.e., columns labeled “vaccinated anywhere” in Table 2),
the mean ICER estimate based on Total Program Cost 1
was $71.74 per incremental-student-vaccinated in Year
2, which was lower than $71.78 in Year 1. However, be-
cause the estimated 95 % CI in Year 2 ($59.75, $84.47)
overlaps with that in Year 1 ($60.32, $83.77), there is nosignificant difference in Total Program Cost 1 between
Years 1 and 2.
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